Galmed Pharma (GLMD): Cutting PT On Dilution - HC Wainwright
Tweet Send to a Friend
H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Galmed Pharmaceuticals (NASDAQ: GLMD) noting multiple upcoming catalysts ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE